Guggenheim Initiates Rapt Therapeutics With Buy Rating and $70 Price Target
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameRAPT Therapeutics, Inc.
-
Registration countryUSA
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









